Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits 
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
NEW HAVEN, Conn., Feb. 28, 2017 -- Melinta Therapeutics, a privately held company developing novel antibiotics to treat serious bacterial infections, announced today the U.S. Food and Drug Administration (FDA) has accepted an Investigational New Drug (IND) application for topical radezolid for the treatment of mild-to-moderate acne. Melinta and a partner are collaborating on the development of radezolid for the treatment of dermatological conditions including acne under a December 2014 agreement. Since that time, the companies have successfully developed a formulation and completed IND-enabling preclinical development. Melinta and its partner will be collaborating on designing the clinical development plan, and anticipate initiating a Phase 1 clinical trial in early 2017.
About Radezolid
Radezolid is a second-generation oxazolidinone discovered by Melinta scientists using proprietary, structure-based design, to achieve higher ribosomal binding affinity, minimal off-target activity, and a broader spectrum of antimicrobial activity than is currently available in the class. For more information, please visit the company website.
About Melinta Therapeutics
Melinta Therapeutics, Inc. is dedicated to saving lives threatened by the global public health crisis of bacterial infections, through the development of novel antibiotics that provide new and better therapeutic solutions. Melinta has submitted an NDA to the FDA for its late-stage investigational antibiotic, Baxdela, for the treatment of acute bacterial skin and skin structure infections (ABSSSI). Baxdela is also being studied in Phase 3 clinical development for the treatment of community-acquired bacterial pneumonia (CABP). Melinta is committed to developing, through the application of Nobel Prize-winning science, a new class of antibiotics designed to overcome the multi- and extremely-drug-resistant pathogens for which there are few to no options, known collectively as ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter species and Escherichia coli), which cause the majority of life-threatening hospital infections.
Melinta Therapeutics is privately held and backed by Vatera Healthcare Partners (www.vaterahealthcare.com) and Malin Corporation plc (www.malinplc.com) among other private investors. The company is headquartered in New Haven, CT with offices in Lincolnshire, IL. Visit www.melinta.com for more information.
For More Information: Lyn Baranowski (312) 724-9400 [email protected] Aline Sherwood (312) 238-8957 [email protected]
